1. [PDF] Clinical Benefit of Ripretinib Dose Escalation After Disease ...
Ripretinib, a switch-control TKI, inhibits a broad range of known primary and secondary KIT and PDGFRA mutations that drive drug resistance by regulating the ...
2. [PDF] Clinical Aspects of Pediatric and Adult Onset Mastocytosis in the Skin
Chapter 1 Introduction & Aims of the thesis. Chapter 2 Recent advances in mast cell-related skin diseases: Particular focus on mastocytosis and urticaria.
3. [PDF] Incorporation of Salivary Gland Ultrasonography Into the American ...
Exclusion criteria were age <18 years, the presence of an associated systemic autoimmune disease (e.g., rheuma- toid arthritis, systemic lupus erythematosus), ...
4. Molecular Target Modulation, Imaging, and Clinical Evaluation of ...
Here, we present the final analysis of safety, pharmacokinetics (PK), and clinical and biological activity of sunitinib in a phase I/II trial of GIST patients ...
To evaluate sunitinib activity and potential cellular and molecular correlates in gastrointestinal stromal tumor (GIST) patients after imatinib failure, in addition to assessing the safety and pharmacokinetics (PK) of different dose schedules. In ...
5. [PDF] Maastricht University
1 jan 2018 · Please check the document version of this publication: • A submitted manuscript is the version of the article upon submission and before ...
6. [PDF] immunogenetics of inflammation and infection - VU Research Portal
The work described in this thesis was performed at the VU University Medical Center, Laboratory of Immunogenetics. (Head: Prof. A.S. Peña, MD, PhD, FRCP, ...
7. [PDF] Ripretinib in patients with advanced gastrointestinal stromal tumours ...
5 jun 2020 · (17·4 vs 17·4 months, respectively; p=0·572) as second- line or ... 1 Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function ...
8. Suzanne Hirota | Walt Disney Animation Studios Wikia - Fandom
Bevat niet: 17 | Resultaten tonen met:17
Suzanne Hirota is an inbetween artist at Walt Disney Animation Studios.
9. [PDF] Novel approaches in soft tissue sarcomas, with an emphasis on ...
increasing age at diagnosis contributing to a higher risk of death. Compared ... lacking the extracellular region encoded by exons 2–17, designated ALK Δ2-17 ( ...
